Drug intelligence / Profile preview

VCC-002

Development stage: Preclinical
Lead developer: Vaccentis
Modality: Vaccines & Immunotherapeutics

Overview

VCC-002 is a therapeutic cancer vaccine currently in preclinical development by Vaccentis AG for the treatment of metastatic renal cell carcinoma (mRCC). The vaccine is based on the company's All Individualized Precision Immunotherapy (AIPI) platform, which utilizes an autologous approach to generate a personalized treatment based on the unique antigen profile of a patient's own tumor. By priming the immune system with these patient-specific tumor antigens, VCC-002 is designed to induce a targeted immune response capable of recognizing and attacking metastatic tumor cells. It serves as a follow-on candidate to VCC-001, which is being developed for the adjuvant treatment of renal cell carcinoma post-nephrectomy.

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on VCC-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VCC-002.

Explore the full profile